Patients with esophageal cancer that had locally advanced diseases or with unresectable
diseases are being asked to participate in this phase I/II study.
This phase I/II study is being conducted to determine the maximum-tolerated dose (MTD),
dose-limiting toxicity (DLT), and efficacy of IMRT combined with S-1 and Oxaliplatin (SOX)
based chemotherapy for unresectable locally advanced esophageal cancer.